{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T14:37:37Z","timestamp":1782311857679,"version":"3.54.5"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["U01TR003715"],"award-info":[{"award-number":["U01TR003715"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008615","name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["K12TR004416"],"award-info":[{"award-number":["K12TR004416"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Children with subtotally resected pediatric low-grade glioma (pLGG) often face multiple lines of treatment, which are seldom capable of eliminating the entire tumor. Genomics-based biomarkers are often used to select targeted therapies, but this paradigm only yields overall response rates of ~50%. Functional precision medicine (FPM), where patient-specific therapeutic efficacy is evaluated by directly treating individuals\u2019 tumor outside their body, can predict individualized drug responses for some cancers, but pLGG is notoriously difficult to maintain outside the body, limiting development of FPM for pLGG. We describe the first platform that can maintain, treat, and analyze zero-passage pLGG tumor tissue\n                    <jats:italic>ex vivo<\/jats:italic>\n                    , facilitating FPM testing. Here, we tested pLGG tumors on our previously validated Screening Live Cancer Explants (SLiCE) platform, which allows engraftment and testing of diverse CNS tumor types atop organotypic brain slice cultures (OBSCs). After ensuring reproducible engraftment and maintenance of all three living pLGG tumor tissues on SLiCE, we measured MAPK pathway response to targeted therapies via immunoblotting. In the tested BRAF KIAA1549 fusion+ tumor, Western blot demonstrated maintenance of expected paradoxical MAPK upregulation in response to dabrafenib treatment. We then measured tumor response to targeted therapies on SLiCE. As expected, none of the BRAF KIAA1549 fusion+ pLGG tumors were sensitive to dabrafenib treatment. Two out of the three tumors demonstrated predicted sensitivity to trametinib, whereas one tumor did not. While no clinical correlates were measured in this proof-of-concept study, this mixed response to MEK inhibition on SLiCE is representative of heterogeneous real-world clinical responses. Together, these data demonstrate the feasibility of SLiCE to become a new functional biomarker of response in a tumor type where functional models are exceptionally rare, establishing a foundation for future individualized treatment strategies.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0331423","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:23:16Z","timestamp":1772734996000},"page":"e0331423","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["An ex vivo functional biomarker of treatment response in pediatric low-grade glioma"],"prefix":"10.1371","volume":"21","author":[{"given":"Nichole M.","family":"Artz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6486-3230","authenticated-orcid":true,"given":"Breanna","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ebbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Darawsheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaneekar","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebimpe","family":"Adefolaju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-1017","authenticated-orcid":true,"given":"Dimitri","family":"Trembath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Elton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hingtgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-5823","authenticated-orcid":true,"given":"Andrew B.","family":"Satterlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"key":"pone.0331423.ref001","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac161","article-title":"CBTRUS statistical report: Pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018","volume":"24","author":"QT Ostrom","year":"2022","journal-title":"Neuro Oncol"},{"issue":"1","key":"pone.0331423.ref002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/neuonc\/noad195","article-title":"Pediatric low-grade glioma: State-of-the-art and ongoing challenges","volume":"26","author":"J Fangusaro","year":"2024","journal-title":"Neuro Oncol"},{"issue":"2","key":"pone.0331423.ref003","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3171\/2024.2.PEDS23236","article-title":"The role of reoperation in pediatric cerebellar pilocytic astrocytoma","volume":"34","author":"MM Kameda-Smith","year":"2024","journal-title":"J Neurosurg Pediatr"},{"issue":"7","key":"pone.0331423.ref004","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/pbc.24958","article-title":"Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database","volume":"61","author":"P Bandopadhayay","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"pone.0331423.ref005","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/cncr.29907","article-title":"Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study","volume":"122","author":"R Krishnatry","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"pone.0331423.ref006","first-page":"583","article-title":"Disease burden and healthcare utilization in pediatric low-grade glioma: A United States retrospective study of linked claims and electronic health records","volume":"11","author":"S Zelt","year":"2024","journal-title":"Neurooncol Pract"},{"issue":"2","key":"pone.0331423.ref007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"D Malani","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"pone.0331423.ref008","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"C Kornauth","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"pone.0331423.ref009","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.1038\/s41598-019-47578-7","article-title":"Prospective validation of an ex vivo, patient-derived 3D spheroid model for response predictions in newly diagnosed ovarian cancer","volume":"9","author":"S Shuford","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0331423.ref010","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"H Peterziel","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"16","key":"pone.0331423.ref011","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/0008-5472.CAN-22-3702","article-title":"High-throughput drug screening of primary tumor cells identifies therapeutic strategies for treating children with high-risk cancer","volume":"83","author":"C Mayoh","year":"2023","journal-title":"Cancer Res"},{"issue":"4","key":"pone.0331423.ref012","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"AM Acanda De La Rocha","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"pone.0331423.ref013","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/neuonc\/noad125","article-title":"Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation","volume":"25","author":"T Milde","year":"2023","journal-title":"Neuro Oncol"},{"key":"pone.0331423.ref014","doi-asserted-by":"crossref","first-page":"1346949","DOI":"10.3389\/fonc.2023.1346949","article-title":"Pediatric low-grade glioma models: Advances and ongoing challenges","volume":"13","author":"GM Yvone","year":"2024","journal-title":"Front Oncol"},{"key":"pone.0331423.ref015","doi-asserted-by":"crossref","first-page":"101042","DOI":"10.1016\/j.xcrm.2023.101042","article-title":"A living ex vivo platform for functional, personalized brain cancer diagnosis","volume":"4","author":"B Mann","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"pone.0331423.ref016","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/s41467-024-45979-5","article-title":"Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma","volume":"15","author":"X Cheng","year":"2024","journal-title":"Nat Commun"},{"key":"pone.0331423.ref017","article-title":"Automated computer vision and dose-response modeling improve throughput and accuracy of an ex vivo functional precision medicine platform","author":"N Bell","year":"2025","journal-title":"Res Sq"},{"issue":"8","key":"pone.0331423.ref018","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1158\/1535-7163.MCT-24-1098","article-title":"Repurposing the DNA Labeling Agent EdU for therapy against heterogeneous patient glioblastoma","volume":"24","author":"H Kaanoglu","year":"2025","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"pone.0331423.ref019","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/neuonc\/noz138","article-title":"Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma","volume":"21","author":"AB Satterlee","year":"2019","journal-title":"Neuro Oncol"},{"key":"pone.0331423.ref020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.omto.2022.06.004","article-title":"Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence","volume":"26","author":"AB Satterlee","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"pone.0331423.ref021","article-title":"Rapid functional drug screening of passage-zero patient brain tumor tissues ex vivo: Results from a clinical feasibility study","author":"A Satterlee","year":"2025","journal-title":"Res Sq"},{"issue":"21","key":"pone.0331423.ref022","doi-asserted-by":"crossref","first-page":"12984","DOI":"10.3390\/ijms232112984","article-title":"In vitro\/in vivo translation of synergistic combination of MDM2 and MEK inhibitors in melanoma using PBPK\/PD modelling: Part I","volume":"23","author":"J Witkowski","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"pone.0331423.ref023","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.3892\/or.2017.5963","article-title":"Phenotype characterization of human melanoma cells resistant to dabrafenib","volume":"38","author":"FG Cordaro","year":"2017","journal-title":"Oncol Rep"},{"issue":"4","key":"pone.0331423.ref024","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/bjc.2014.139","article-title":"Mechanism and consequences of RAF kinase activation by small-molecule inhibitors","volume":"111","author":"M Holderfield","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"pone.0331423.ref025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","article-title":"BRAF - a tumour-agnostic drug target with lineage-specific dependencies","volume":"21","author":"AJ Hanrahan","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pone.0331423.ref026","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/0008-5472.CAN-15-2900-T","article-title":"Secondary tumors arising in patients undergoing BRAF inhibitor therapy exhibit increased BRAF-CRAF heterodimerization","volume":"76","author":"L Boussemart","year":"2016","journal-title":"Cancer Res"},{"issue":"7","key":"pone.0331423.ref027","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","article-title":"Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma","volume":"10","author":"GT Gibney","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"pone.0331423.ref028","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"LB Kilburn","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"pone.0331423.ref029","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1227\/NEU.0b013e318214a66e","article-title":"Primary neurosurgery for pediatric low-grade gliomas: A prospective multi-institutional study from the Children\u2019s Oncology Group","volume":"68","author":"JH Wisoff","year":"2011","journal-title":"Neurosurgery"},{"issue":"12","key":"pone.0331423.ref030","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","volume":"389","author":"E Bouffet","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"pone.0331423.ref031","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1200\/JCO.2011.36.6054","article-title":"Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: A report from the Children\u2019s Oncology Group","volume":"30","author":"JL Ater","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"pone.0331423.ref032","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/JCO.2011.34.5843","article-title":"Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma","volume":"30","author":"E Bouffet","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"pone.0331423.ref033","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: A Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"A Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"pone.0331423.ref034","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1186\/s12885-019-6442-2","article-title":"A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK\/ERK pathway: TRAM-01","volume":"19","author":"S Perreault","year":"2019","journal-title":"BMC Cancer"},{"issue":"7","key":"pone.0331423.ref035","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial","volume":"20","author":"J Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"pone.0331423.ref036","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","article-title":"Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade glioma: Results from a Phase I\/IIa Study","volume":"25","author":"DR Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0331423.ref037","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1200\/JCO.22.01000","article-title":"Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma","volume":"41","author":"E Bouffet","year":"2023","journal-title":"J Clin Oncol"},{"key":"pone.0331423.ref038"},{"issue":"2","key":"pone.0331423.ref039","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.11.011","article-title":"Lymphoma study titles on ClinicalTrials.gov lack details necessary for study identification","volume":"20","author":"A Toure","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"pone.0331423.ref040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS10067","article-title":"LOGGIC\/FIREFLY-2: A phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration","volume":"41","author":"CM van Tilburg","year":"2023","journal-title":"JCO"},{"issue":"7","key":"pone.0331423.ref041","doi-asserted-by":"crossref","first-page":"11460","DOI":"10.18632\/oncotarget.14004","article-title":"Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing","volume":"8","author":"F Selt","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"pone.0331423.ref042","article-title":"Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development","volume":"4","author":"DA Bax","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"pone.0331423.ref043","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/noac199","article-title":"BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma","volume":"25","author":"F Selt","year":"2023","journal-title":"Neuro Oncol"},{"issue":"5","key":"pone.0331423.ref044","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1093\/neuonc\/noaa263","article-title":"Conditional reprogramming culture conditions facilitate growth of lower-grade glioma models","volume":"23","author":"M Yuan","year":"2021","journal-title":"Neuro Oncol"},{"issue":"24","key":"pone.0331423.ref045","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.1158\/1078-0432.CCR-13-0842","article-title":"Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma","volume":"19","author":"HK Bid","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"pone.0331423.ref046","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/neuonc\/noac183","article-title":"The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models","volume":"25","author":"R Sigaud","year":"2023","journal-title":"Neuro Oncol"},{"issue":"6","key":"pone.0331423.ref047","first-page":"774","article-title":"A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas","volume":"19","author":"Y Sun","year":"2017","journal-title":"Neuro Oncol"},{"key":"pone.0331423.ref048","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1101\/gad.310797.117","article-title":"Athymic mice reveal a requirement for T-cell-microglia interactions in establishing a microenvironment supportive of Nf1 low-grade glioma growth","volume":"32","author":"Y Pan","year":"2018","journal-title":"Genes Dev"},{"issue":"1","key":"pone.0331423.ref049","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1038\/s41467-020-15770-3","article-title":"Midkine activation of CD8+ T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth","volume":"11","author":"X Guo","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0331423.ref050","article-title":"Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation","volume":"4","author":"A de Andrade Costa","year":"2021","journal-title":"Neurooncol Adv"},{"issue":"4","key":"pone.0331423.ref051","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.22576","article-title":"Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program","volume":"55","author":"EA Kolb","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"pone.0331423.ref052"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:23:25Z","timestamp":1772735005000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0331423"}},"subtitle":[],"editor":[{"given":"Santosh K.","family":"Patnaik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,5]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0331423","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,5]]}}}